Malaria vaccines

WHO recommends the use of malaria vaccines (RTS,S/AS01 and R21/Matrix-M) for the prevention of P. falciparum malaria for children living in endemic areas, prioritizing areas of moderate and high transmission. ^{Go to footnote 11} Currently available vaccines reduce disease burden (clinical and severe malaria and all-cause child deaths), but do not prevent infection or block transmission. The delivery of malaria vaccines should be part of a comprehensive malaria control strategy and integrated into primary health care service delivery. 

Malaria vaccine is one of several WHO-recommended high-impact interventions (all only partially protective); higher impact can be achieved through a mix of tools determined by the country through subnational tailoring, and considering local context. ^{Go to footnote 22, Go to footnote 33} 

The burden of malaria in Africa has been reduced substantially in recent decades as a result of scaled-up malaria control measures. However, since 2015, the rate of progress in reducing both malaria cases and deaths has stalled; in some countries with high malaria burden, the annual number of malaria cases has risen. Increased use of current control and prevention tools, which now include malaria vaccine, and the addition of new tools, strategies and enhanced problem-solving approaches are needed to further improve malaria control. ^{Go to footnote 44}